Gene-Editing Therapy for Rare Blood Disorder to Become Available in England

Spread the love

A New Lease on Life

The National Health Service (NHS) in England has announced a partnership with drugmakers to bring a revolutionary gene-editing therapy, Casgevy, to patients with a rare blood disorder. This treatment, which uses CRISPR technology, has the potential to be a cure for patients with transfusion-dependent beta thalassaemia, a life-limiting genetic condition that requires regular blood transfusions to survive.

A Life-Changing Treatment

The therapy, which is administered as a one-time infusion, involves extracting stem cells from a patient’s bone marrow, altering the gene to remove the condition, and then infusing the treated cells back into the patient. This treatment is expected to be fast-tracked to patients who could benefit from its life-changing promises. The NHS Chief Executive, Amanda Pritchard, hailed the treatment as “one-off” and “life-changing,” promising a new lease on life for patients.

Breaking Free from Regular Transfusions

The treatment offers a significant improvement over existing treatments, which require patients to receive regular blood transfusions every three to five weeks. In clinical trials, 93% of patients who received Casgevy did not need a transfusion for at least a year after treatment, raising hopes that it could cure the condition. Patients with beta thalassaemia currently experience painful side effects and undergo regular transfusions, which severely impact their quality of life.

Hope and Relief for Patients

The news has brought hope and relief to patients like Kirthana Balachandran, a medical student from West London who was diagnosed with thalassaemia at just three months old. She fears that relying on regular blood transfusions for the rest of her life would be daunting. With Casgevy, she sees the possibility of living a life free from the burden of transfusions and the hope of living longer.

Global Impact

The approval of Casgevy is a significant milestone in the development of gene-editing technology. As Dr. James Davies, an associate professor of genomics at the University of Oxford, notes, this technology has the potential to be used for treating many other genetic diseases. With this breakthrough, patients with rare genetic conditions may finally have access to effective treatments that can change their lives.


SOURCE: Ref Image from Yahoo News Uk

Views:1021 2
Website | + posts

Whether writing about complex technical topics or breaking news stories, my writing is always clear, concise, and engaging. My dedication to my craft and passion for storytelling have earned me a reputation as a highly respected article writer.


Spread the love